» Articles » PMID: 8565901

Reduction of Azo Dyes and Nitroaromatic Compounds by Bacterial Enzymes from the Human Intestinal Tract

Overview
Date 1995 Jun 1
PMID 8565901
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Several anaerobic bacteria from the human intestinal tract are capable of reducing azo dyes and nitropolycyclic aromatic hydrocarbons to the corresponding aromatic amines with enzymes that have azoreductase and nitroreductase activities. The majority of bacteria with these activities belong to the genera Clostridium and Eubacterium. The azoreductases and nitroreductases from three Clostridium strains and one Eubacterium strain were studied. Both enzymes were produced constitutively in each of the bacteria; the enzymes from various bacteria had different electrophoretic mobilities. The azoreductases from all of the bacteria had immunological homology, as was evident from the cross-reactivity of an antibody raised against the azoreductase of C. perfringens with azoreductases from other bacteria. Comparison of azoreductases and nitroreductases showed that they both had identical electrophoretic mobilities on polyacrylamide gels and reacted with the antibody against the azoreductase from C. perfringens. Furthermore, the nitroaromatic compounds competitively inhibited the azoreductase activity. The data indicate that the reduction of both nitroaromatic compounds and azo dyes may be carried out by the same enzyme, which is possibly a flavin adenine dinucleotide dehydrogenase that is synthesized throughout the cell and not associated with any organized subcellular structure.

Citing Articles

Mass Spectrometry Applications to Study Human Microbiome.

Raslan M, Raslan S, Shehata E, Mahmoud A, Viana M, Aburjaile F Adv Exp Med Biol. 2024; 1443:87-101.

PMID: 38409417 DOI: 10.1007/978-3-031-50624-6_5.


Novel Techniques and Models for Studying the Role of the Gut Microbiota in Drug Metabolism.

Tan J, Fu B, Zhao X, Ye L Eur J Drug Metab Pharmacokinet. 2023; 49(2):131-147.

PMID: 38123834 DOI: 10.1007/s13318-023-00874-0.


Exploring the role of gut microbiota in advancing personalized medicine.

Huang G, Khan R, Zheng Y, Lee P, Li Q, Khan I Front Microbiol. 2023; 14:1274925.

PMID: 38098666 PMC: 10720646. DOI: 10.3389/fmicb.2023.1274925.


Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Fan J, Jiang T, He D Front Immunol. 2023; 14:1189036.

PMID: 37841256 PMC: 10568326. DOI: 10.3389/fimmu.2023.1189036.


Dissecting the human gut microbiome to better decipher drug liability: A once-forgotten organ takes center stage.

Cai J, Auster A, Cho S, Lai Z J Adv Res. 2023; 52:171-201.

PMID: 37419381 PMC: 10555929. DOI: 10.1016/j.jare.2023.07.002.


References
1.
Gingell R, Walker R . Mechanisms of azo reduction by Streptococcus faecalis. II. The role of soluble flavins. Xenobiotica. 1971; 1(3):231-9. DOI: 10.3109/00498257109033172. View

2.
Zachariah P, Juchau M . The role of gut flora in the reduction of aromatic nitro-groups. Drug Metab Dispos. 1974; 2(1):74-8. View

3.
Fujita S, Peisach J . The stimulation of microsomal azoreduction by flavins. Biochim Biophys Acta. 1982; 719(2):178-89. DOI: 10.1016/0304-4165(82)90087-3. View

4.
Cerniglia C, Freeman J, Franklin W, Pack L . Metabolism of azo dyes derived from benzidine, 3,3'-dimethyl-benzidine and 3,3'-dimethoxybenzidine to potentially carcinogenic aromatic amines by intestinal bacteria. Carcinogenesis. 1982; 3(11):1255-60. DOI: 10.1093/carcin/3.11.1255. View

5.
Howard P, Beland F, Cerniglia C . Reduction of the carcinogen 1-nitropyrene to 1-aminopyrene by rat intestinal bacteria. Carcinogenesis. 1983; 4(8):985-90. DOI: 10.1093/carcin/4.8.985. View